Cayuga Biotech

Cayuga Biotech is an innovative biopharmaceutical company targeting the massive and underserved global market for hemorrhage control. Founded on proprietary science, the company is developing novel, biomimetic small molecule therapies aimed at rapidly stopping bleeding in situations where current treatments fail, such as trauma, surgery, and in patients on blood thinners. Led by a seasoned team with deep experience in drug development and commercialization, including prior work on approved hemorrhage therapeutics, Cayuga is positioned to advance its pipeline through key preclinical and clinical milestones. The company operates as a private, pre-revenue entity seeking to transform outcomes in a critical area of medicine.

Proprietary biomimetic science platform for developing small molecule therapeutics that harness the body's innate hemostatic mechanisms to control life-threatening bleeding.

Cayuga competes in the hemostasis market with approved products like topical hemostats, tranexamic acid, and specific reversal agents (e.g., Andexxa, Praxbind). It also faces competition from other biotechs and large pharma companies developing next-generation therapies for trauma and surgical bleeding. Differentiation will hinge on demonstrating superior speed, efficacy, and breadth of application compared to existing standards.